

Alexander Camacho

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6622077/publications.pdf>

Version: 2024-02-01

18
papers

891
citations

686830

13
h-index

839053

18
g-index

23
all docs

23
docs citations

23
times ranked

1319
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1085.	3.8	403
2	Soluble Urokinase Receptor and Acute Kidney Injury. <i>New England Journal of Medicine</i> , 2020, 382, 416-426.	13.9	149
3	Natriuretic Peptides as Inclusion Criteria in Clinical Trials. <i>JACC: Heart Failure</i> , 2020, 8, 347-358.	1.9	53
4	Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 127-136.	1.9	47
5	Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020, 13, e006946.	1.6	28
6	Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. <i>Circulation</i> , 2021, 144, 180-182.	1.6	28
7	Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 137-145.	1.9	27
8	Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2021, 14, e008410.	1.6	27
9	Comparison of Transvalvular Aortic Mean Gradients Obtained by Intraprocedural Echocardiography and Invasive Measurement in Balloon and Self-Expanding Transcatheter Valves. <i>Journal of the American Heart Association</i> , 2021, 10, e021014.	1.6	22
10	Sex-based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. <i>European Journal of Heart Failure</i> , 2020, 22, 2018-2025.	2.9	21
11	Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 42-51.	1.9	20
12	Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020, 13, e007829.	1.6	18
13	The Health Resources and Services Administration Diversity Data Collection. <i>Public Health Reports</i> , 2014, 129, 51-56.	1.3	13
14	Diversifying the Health-Care Workforce Begins at the Pipeline: A 5-Year Synthesis of Processes and Outputs of the Scholarships for Disadvantaged Students Program. <i>Evaluation and the Health Professions</i> , 2017, 40, 127-150.	0.9	11
15	Proteomic Signatures During Treatment in Different Stages of Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006794.	1.6	10
16	Plasma Soluble Suppression of Tumorigenicity-2 Associates with Ventilator Liberation in Acute Hypoxemic Respiratory Failure. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1257-1265.	2.5	8
17	Patient- and Process-Related Contributors to the Underuse of Aortic Valve Replacement and Subsequent Mortality in Ambulatory Patients With Severe Aortic Stenosis. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	5
18	Financing Primary Prevention. , 2014, , 224-235.		0